{"nctId":"NCT03921424","briefTitle":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","startDateStruct":{"date":"2019-11-05","type":"ACTUAL"},"conditions":["Pneumococcal Infections"],"count":407,"armGroups":[{"label":"V114","type":"EXPERIMENTAL","interventionNames":["Biological: V114","Biological: PNEUMOVAX™23"]},{"label":"Prevnar 13™","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Prevnar 13™","Biological: PNEUMOVAX™23"]}],"interventions":[{"name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"name":"Prevnar 13™","otherNames":[]},{"name":"PNEUMOVAX™23","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female between the ages of 6 and 17 years (inclusive) infected with HIV and has a Cluster of Differentiation 4+ (CD4+) T-cell count ≥200 cells/µL and plasma HIV ribonucleic acid (RNA) \\<50,000 copies/mL\n* Is Pneumococcal Conjugate Vaccine (PCV) naïve, previously vaccinated with a \\<13-valent PCV, partially vaccinated with Prevnar 13™, or has a history of previous Prevnar 13™ vaccination ≥3 years before Visit 2 (Day 1)\n* Is PnPs vaccine naïve or has a history of 1 previous PnPs vaccination ≥5 years before Visit 2 (Day 1)\n* Female participant: not pregnant, not breastfeeding and 1) not of childbearing potential, or 2) of childbearing potential and agrees to practice contraception through 6 weeks after administration of last dose of the study vaccine.\n\nExclusion Criteria:\n\n* History of World Health Organization (WHO) HIV classification of clinical Stage 4 disease within the past 12 months\n* History of invasive pneumococcal disease\n* Known hypersensitivity to any vaccine component\n* Known or suspected congenital immunodeficiency (other than HIV infection), functional or anatomic asplenia, or history of autoimmune disease\n* Bleeding disorder contraindicating intramuscular vaccinations\n* History of malignancy ≤5 years prior to signing informed consent/assent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n* Female participant: positive urine or serum pregnancy test\n* Expect to receive any pneumococcal vaccine during the study outside of the protocol\n* Receiving immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease\n* Received a blood transfusion or blood products within 6 months of enrollment\n* Participated in another clinical study of an investigational product within 2 months of enrollment\n* Current user of recreational or illicit drugs or history of drug or alcohol abuse or dependence","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With V114 or Prevnar 13™","description":"An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 1 with either V114 or Prevnar 13™, the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, hard lump/induration, tenderness/pain, and swelling.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"5.7"},{"groupId":"OG001","value":"5.9","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"6.5"},{"groupId":"OG001","value":"6.4","spread":"3.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":"48.1"},{"groupId":"OG001","value":"53.9","spread":"46.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"22.5"},{"groupId":"OG001","value":"21.6","spread":"16.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With V114 or Prevnar 13™","description":"An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 1 with either V114 or Prevnar 13™, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were joint pain/arthralgia, tiredness/fatigue, headache, muscle pain/myalgia, and hives or welts/urticaria.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4","spread":"5.7"},{"groupId":"OG001","value":"10.3","spread":"6.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"4.6"},{"groupId":"OG001","value":"8.3","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"10.2"},{"groupId":"OG001","value":"10.8","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.0","spread":"27.5"},{"groupId":"OG001","value":"25.5","spread":"19.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.0"},{"groupId":"OG001","value":"1.5","spread":"0.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE) Following Vaccination 1 (V114 or Prevnar 13™) or Vaccination 2 (PNEUMOVAX™23) Through Completion of Study","description":"An SAE is an AE that results in death, is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is an other important medical event deemed such by medical or scientific judgment. The percentage of participants with a vaccine-related SAE following Vaccination 1 (with either V114 or Prevnar 13™) or Vaccination 2 (PNEUMOVAX™23) through completion of study participation was reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-PnPs Serotype-specific IgG Geometric Mean Concentrations (GMCs) at 30 Days Following Vaccination With V114 or Prevnar 13™","description":"The GMC of serotype-specific IgG for the serotypes contained in V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":null},{"groupId":"OG001","value":"3.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"0.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":null},{"groupId":"OG001","value":"4.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":null},{"groupId":"OG001","value":"2.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.98","spread":null},{"groupId":"OG001","value":"7.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.44","spread":null},{"groupId":"OG001","value":"6.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.84","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":null},{"groupId":"OG001","value":"4.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.38","spread":null},{"groupId":"OG001","value":"18.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.18","spread":null},{"groupId":"OG001","value":"5.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.20","spread":null},{"groupId":"OG001","value":"14.78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.76","spread":null},{"groupId":"OG001","value":"8.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.71","spread":null},{"groupId":"OG001","value":"6.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.28","spread":null},{"groupId":"OG001","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.53","spread":null},{"groupId":"OG001","value":"0.29","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Solicited Injection-Site Adverse Event Following Vaccination With PNEUMOVAX™23","description":"An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 2 with PNEUMOVAX™23 (PPV23), the percentage of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, hard lump/induration, tenderness/pain, and swelling.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"6.5"},{"groupId":"OG001","value":"12.4","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":"13.2"},{"groupId":"OG001","value":"13.4","spread":"9.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":"44.6"},{"groupId":"OG001","value":"55.0","spread":"47.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":"40.3"},{"groupId":"OG001","value":"34.7","spread":"28.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Solicited Systemic Adverse Event Following Vaccination With PNEUMOVAX™23","description":"An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Following Vaccination 2 with PNEUMOVAX™23, the percentage of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were joint pain/arthralgia, tiredness/fatigue, headache, muscle pain/myalgia, and hives or welts/urticaria.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"8.5"},{"groupId":"OG001","value":"8.4","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":"8.1"},{"groupId":"OG001","value":"11.4","spread":"7.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.3","spread":"6.5"},{"groupId":"OG001","value":"9.4","spread":"5.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","spread":"36.4"},{"groupId":"OG001","value":"39.1","spread":"32.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"},{"groupId":"OG001","value":"0.5","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Anti-PnPs Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 30 Days Following Vaccination With V114 or Prevnar 13™","description":"The GMT of serotype-specific OPA for the serotypes contained in V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplexed opsonophagocytic assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"353.4","spread":null},{"groupId":"OG001","value":"398.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"330.0","spread":null},{"groupId":"OG001","value":"301.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6078.3","spread":null},{"groupId":"OG001","value":"9172.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"847.6","spread":null},{"groupId":"OG001","value":"642.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14274.6","spread":null},{"groupId":"OG001","value":"11915.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17636.5","spread":null},{"groupId":"OG001","value":"15052.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17574.4","spread":null},{"groupId":"OG001","value":"18519.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4800.0","spread":null},{"groupId":"OG001","value":"5879.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18444.3","spread":null},{"groupId":"OG001","value":"17920.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4556.2","spread":null},{"groupId":"OG001","value":"3543.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8176.4","spread":null},{"groupId":"OG001","value":"8690.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3711.8","spread":null},{"groupId":"OG001","value":"3277.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11693.1","spread":null},{"groupId":"OG001","value":"11933.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10791.3","spread":null},{"groupId":"OG001","value":"503.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36357.0","spread":null},{"groupId":"OG001","value":"5520.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PnPs Serotype-specific OPA GMTs at 30 Days Following Vaccination With PNEUMOVAX™23 (Week 12)","description":"The GMT of serotype-specific OPA for the serotypes contained in V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using a multiplexed opsonophagocytic assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"326.4","spread":null},{"groupId":"OG001","value":"337.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"327.2","spread":null},{"groupId":"OG001","value":"384.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5445.7","spread":null},{"groupId":"OG001","value":"7526.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"985.6","spread":null},{"groupId":"OG001","value":"939.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10208.7","spread":null},{"groupId":"OG001","value":"10699.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13774.8","spread":null},{"groupId":"OG001","value":"12745.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17415.9","spread":null},{"groupId":"OG001","value":"19140.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5135.9","spread":null},{"groupId":"OG001","value":"6152.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17207.5","spread":null},{"groupId":"OG001","value":"16461.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3635.1","spread":null},{"groupId":"OG001","value":"3369.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7613.7","spread":null},{"groupId":"OG001","value":"8838.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3694.8","spread":null},{"groupId":"OG001","value":"3904.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10216.7","spread":null},{"groupId":"OG001","value":"10086.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8756.1","spread":null},{"groupId":"OG001","value":"6958.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34173.6","spread":null},{"groupId":"OG001","value":"30651.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-PnPs Serotype-specific IgG GMCs at 30 Days Following Vaccination With PNEUMOVAX™23 (Week 12)","description":"The GMC of serotype-specific IgG for the serotypes contained in V114 (13 serotypes shared with Prevnar 13™ and 2 serotypes unique to V114) was determined using an electrochemiluminescence assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.58","spread":null},{"groupId":"OG001","value":"3.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":null},{"groupId":"OG001","value":"1.08","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":null},{"groupId":"OG001","value":"3.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.01","spread":null},{"groupId":"OG001","value":"3.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":null},{"groupId":"OG001","value":"4.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.12","spread":null},{"groupId":"OG001","value":"4.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.10","spread":null},{"groupId":"OG001","value":"4.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.69","spread":null},{"groupId":"OG001","value":"4.52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.88","spread":null},{"groupId":"OG001","value":"19.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":null},{"groupId":"OG001","value":"4.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.23","spread":null},{"groupId":"OG001","value":"12.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.56","spread":null},{"groupId":"OG001","value":"7.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.40","spread":null},{"groupId":"OG001","value":"4.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.18","spread":null},{"groupId":"OG001","value":"10.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.76","spread":null},{"groupId":"OG001","value":"6.18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":203},"commonTop":["Injection site pain","Myalgia","Injection site swelling","Injection site induration","Headache"]}}}